Clinical trials: Single Dose
Healthy Subjects
Study Evaluating The Mass Balance And Metabolic Disposition Of SKI-606
This study will assess the mass balance, metabolic disposition, and identification of metabolites following single oral administration of [14C]-SKI-606 in healthy male subjects.
- Trial name
- NCT00757341
- Testing
- SKI-606
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Asthma, Exercise-Induced
A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma
The purpose of this Phase III, multicentre, randomized, double-blind, single-dose, 2-period, crossover study is to assess the efficacy and safety of PT027 (budesonide/albuterol sulfate) metered-dose inhaler compared with placebo…
- Trial name
- BREATH (NCT06245551)
- Testing
- Budesonide/albuterol metered-dose inhaler 160/180 μg
- Where
- 6 sites in Russia
- Volunteers
- 64 people
- Sponsor
- AstraZeneca
Infective Disorder
Clinical Trial of Comparing DA-2902 and DA-2902-R in Healthy Adult Subjects
This study is to compare pharmacokinetics and safety profiles of DA-2902 and DA-2902-R in healthy adult subjects
- Trial name
- NCT07239453
- Testing
- DA-2902, DA-2902-R
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
Rheumatoid Arthritis
VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis
This is a multi-national, multi-centre, placebo-controlled, double-blind, randomized, 4-arm parallel group trial, comparing three different dose levels (80 mg, 160 mg and 320 mg) of veltuzumab to placebo, administered weekly…
- Trial name
- VELVET (NCT01390545)
- Testing
- Veltuzumab
- Where
- 63 sites in United States, Argentina and 9 more
- Volunteers
- 300 people
- Sponsor
- Takeda
Carcinoma, Renal Cell
Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors
This is a two part phase I study in Japanese patients that will determine the safety, tolerability and pharmacokinetics of pazopanib monotherapy and of pazopanib in combination with lapatinib.
- Trial name
- NCT00516672
- Testing
- pazopanib, Lapatinib
- Where
- 2 sites in Japan
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Healthy
Food Study of Cetirizine HCl Tablets 10 mg and Zyrtec® 10 mg
The objective of this study was to investigate the bioequivalence of Mylan's cetirizine HCl tablets to Pfizer's Zyrtec® tablets following a single, oral 10 mg (1 x 10 mg) dose administered under fed conditions.
- Trial name
- NCT00649857
- Testing
- Cetirizine HCl Tablets 10 mg, Zyrtec® 10 mg
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Mylan Pharmaceuticals Inc
Opioid Users
Abuse Potential Study of PF-00345439
This study will determine the relative abuse potential of intact and chewed PF-00345439 (Oxycodone Extended-Release Capsules) compared to crushed oxycodone HCL immediate release (IR) tablets and placebo administered orally to…
- Trial name
- NCT01986283
- Testing
- Capsule, PF-00345439, oxycodone
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Pain Therapeutics
Epilepsy, Healthy Volunteer
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients
This is a dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of SIF001, a monoclonal antibody with the potential to treat epilespy
- Trial name
- NCT07051629
- Testing
- SIF001
- Where
- 10 sites in United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Suninflam Inc
Healthy
Drug-drug Interaction (DDI) Study to Assess Effect of Itraconazole and Rifampicin Upon Olorofim
This is a Phase 1, single-centre, fixed-sequence, open label, drug-drug interaction study in 2 groups of healthy subjects. Group A: to evaluate the effects of itraconazole, a strong inhibitor of cytochrome P450 3A (CYP3A), upon…
- Trial name
- NCT04171739
- Testing
- Itraconazole oral solution, Rifampicin Oral Capsule, Olorofim
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- F2G Ltd
Abuse Potential Study
Study to Evaluate the Relative Abuse Potential of Almorexant in Recreational Drug Users
This was a six-way crossover study with six single-dose treatment sessions. The profile of acute effects on abuse potential measures of different almorexant doses was compared to that of placebo and two doses of zolpidem
- Trial name
- NCT01987739
- Testing
- 200 mg almorexant, 400 mg almorexant, 1000 mg almorexant
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Midnight Pharma, LLC
Gram Positive Bacterial Infection
Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics
This is a research study designed to look at the pharmacokinetics (distribution, breakdown, and removal) and tolerability of a single dose of daptomycin in patients aged 3 months to 24 months who have proven or suspected…
- Trial name
- NCT01019395
- Testing
- Daptomycin
- Where
- 8 sites in United States
- Volunteers
- 23 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Geographic Atrophy
Study of NGM621 in Participants With Geographic Atrophy
This is a multi-center evaluation of NGM621 in an open-label, single-dose and multiple-dose escalation study in participants with Geographic Atrophy secondary to Age-related Macular Degeneration.
- Trial name
- NCT04014777
- Testing
- NGM621
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects
TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)
This study is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of single-dose TD-3504 and single dose 15N2-tofacitinib in healthy subjects and subjects with UC.
- Trial name
- NCT03103412
- Testing
- TD-3504, 15N2-tofacitinib
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Renal Insufficiency
A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of AL-335
The purpose of this study is to evaluate the pharmacokinetics (PK) of a single oral dose of AL-335 in participants with various degrees of impaired renal function (mild, moderate, and severe) compared to participants with normal…
- Trial name
- NCT02894905
- Testing
- AL-335
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Janssen Research & Development, LLC
Advanced Solid Tumors
Evaluation of the Safety and Efficacy of Albumin-bound Docetaxel
This trial is an open-label, single-center, dose-escalation and cohort-expansion Phase I clinical study in patients with advanced solid tumors.
- Trial name
- NCT04471675
- Testing
- Albumin-bound docetaxel
- Where
- China
- Volunteers
- 208 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Idiopathic Pulmonary Fibrosis
Comparative Pharmacokinetic Study of Pirfenidone Modified-Release Tablets in Healthy Subjects Under Fasting and Fed Conditions
A Randomized, Open-Label, Single-Dose, Double-period, Double-Crossover Comparative Study on the Pharmacokinetics of Pirfenidone Modified-Release Tablets by Oral Administration in Healthy Chinese Subjects Under Fasting and Fed…
- Trial name
- NCT06569381
- Testing
- Pirfenidone Modified-Release Tablets
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Overseas Pharmaceuticals, Ltd.
Chronic Myeloid Leukemia, Gastrointestinal Stromal Tumor
A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I)
1. Investigational Product 1. Imatinib mesylate tablet 400 mg 2. Glivec film-coated tablet 100 mg (Comparator) 2. Expected target disease 1. chronic myeloid leukemia 2. Gastrointestinal stromal tumors 3.
- Trial name
- NCT01751919
- Testing
- Imatinib mesylate tablet 400 mg, 1 Tablet, Glivec film-coated tablet 100 mg, 4 Tablets
- Where
- South Korea
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
Cutaneous Leishmaniasis
Reduced Doses of Antimony Plus Ranulocyte Monocyte Colony Stimulating Factor (GM-CSF) for Cutaneous Leishmaniasis
The present study was designed as a randomized, single blind, placebo-controlled, study to evaluate the effect of 400 µg of recombinant human GM-CSF applied intralesionally and associated with half of the total dose of antimony…
- Trial name
- GMCSFSbv (NCT00973128)
- Testing
- GMCSF plus Antimony reduced dose, Meglumine antimoniate
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- Hospital Universitário Professor Edgard Santos
Hypertension
Crossover Bioequivalence Study of Irbesartan 300 mg Tablets Under Fed Conditions
The objective of this study was to prove the bioequivalence of Roxane Laboratories' Irbesartan 300 mg Tablets under fed conditions.
- Trial name
- NCT01712100
- Testing
- Irbesartan, Avapro
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Health Participants
A Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of Single and Multiple Doses of BMS-986209 in Healthy Participants
The purpose of this study is to investigate the safety and tolerability of BMS-986209 in healthy participants. The first-in-human study is designed in 3 parts that vary based on duration and food effect.
- Trial name
- NCT04154800
- Testing
- BMS-986209, Itraconazole, Diltiazem
- Where
- United States
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.